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Part I. Introduction
Nutrients with health enhancing properties, over and above those of conventional foods, provide immense commercial opportunities and possible could have huge public health implications. The food and drink (and recently the pharmaceutical sector) industry has spent millions of dollars in research and development of foods that contain added, technologically developed, ingredients with specific health benefits (Niva, 2007) . These foods are known as functional foods. They were first marketed in Japan in the 1980s, where the term "functional food" was first used by the industry. These foods were intended for consumption as part of a normal diet but were to have a health benefit with a clear and nutritional basis (No-seong Kwak, 2001 ). Essentially functional foods bring science into everyday eating by promising particular and targeted health effects.
In 1990 in Japan, the Ministry for Health and Welfare initiated a policy approving the commercialization of functional foods. In Japanese legal terms, under the Nutrition Improvement Law, the term "Foods for specified health use", or FOSHU, was created and hypoallergenic rice was the first product approved. However different countries have different approaches to food legislation and in the USA there is no definition of functional, or health enhancing foods. Despite this lack of a legal position, the Institute of Medicine of the US National Academy of Sciences defined functional foods as those that, "to encompass potential healthful products, include any modified food, or food ingredient, that may provide a health benefit beyond the traditional nutrients it contains".
Across the European Union the term functional food is rarely used. Instead, in December 2006, the European Union finally agreed, and published, EU Regulation 1924/2006 on nutrition and health claims (European Parliament and Council, 2006) .
Despite the early acceptance in Japan of what a functional food was intended to be, there remains globally no generally accepted legal or scientific definition.
What are nutrition and health claims? In addition to there being no consensus on the definition of what constitutes a functional food, the term "health claim" is also defined differently in different countries. The meaning of the word "claim" itself (as opposed to "health claim") is, however, generally well understood. A widely accepted definition of a "claim" is that of Codex Alimentarius where it is defined as: "any representation, which states, suggests, or implies that a food has certain characteristics relating to its origin, nutritional properties, nature, production, processing, composition or any other quality"(Codex Alimentarius Commission, 1991).
The European Union, in its recently published Regulation on the subject (European Parliament and Council, 2006) , defines a health claim as "any claim that states, suggests or implies that a relationship exists between a food category, a food, or one of its constituents and health" (European Parliament and Council, 2006) .
In the USA, a health claim refers to any statement "that expressly, or by implication characterises, the relationship of any substance to a disease or health-related condition" (US FDA Centre for Food Safety and Applied Nutrition, 2008) .
The term functional food may have no internationally agreed definition but this is not preventing the market for this category of products from growing and expanding in individual countries. According to the Food Marketing Institute, 65 per cent of grocery shoppers try to manage or treat health conditions through diet (Food Marketing Institute, 2004) . The potential exists for global distribution of similar products if agreement on the regulations for "health claims" existed. This article highlights the differences in the requirements in the USA, the EU and Japan and relevant documentation was identified by searching electronic databases including PubMed, Google Scholar and Food Science and Technology Abstracts.
Part II. Regulation and scientific requirements II.1 Japan II.1.1 Regulation of claims in Japan. The results of research and development on the physiological function of foods prompted the Japanese Ministry of Health, Labour and Welfare (MHLW) to establish a regulatory system regarding foods that claim health benefits. This system was aimed at informing the public of health information concerning specific foods. "Foods for specified health use" (FOSHU) was set up by the MHLW in 1991 as the regulatory system to approve statements contained on a label regarding the effects of foods on the human body (Schimizu, 2003) .
Health claims regulations
FOSHU was enacted under the Nutrition Improvement Law and is based on the requirement for scientific evidence to support applications. However, ten years later, in April 2001, the Japanese government enacted a new regulatory system called "Foods with Health Claims" (FHC). This new system integrated FOSHU and revised it to make capsules, tablets or other dosage forms which were commonly consumed as supplements, permissible (Ohama et al., 2006) . It created two different categories FOSHU; and Foods with nutrient function claims (FNFC) (Schimizu, 2003) :
(1) FOSHU. FOSHU labelled food (or products) contain ingredients that have positive effects on human physiological function. It is intended that these products be consumed for the maintenance, or promotion of health, or specifically by people who wish to control certain health conditions. These products must not make medical claims such as "prevent", "cure", "treat" or "diagnose". Examples of existing FOSHU claims are "This product helps to maintain normal blood pressure, blood sugar or cholesterol". A prohibited claim would be "This product cures hypertension". In order to receive FOSHU approval, scientific evidence supporting the claim must be provided by the food business operator. Since December 2007, 755 items had been granted FOSHU status (Yamada et al., 2008) . Existing health claims on FOSHU are classified into eight groups:
. gastro intestinal conditions;
. blood pressure;
. serum cholesterol;
. blood glucose;
. absorption of minerals;
. blood neutral fat;
. dental health; or . bone health (Schimizu, 2003) . To gain approval, the design of the product must be accompanied by the rationale as to how the product makes a contribution to the improvement of the Japanese diet and also the maintenance of good health (Ohama et al., 2006 A report describing the analysis of the designated nutrient constituents and the product's energy content.
. A statement of the method and equipment used in the food's production and an explanation of the quality control system.
These can be summarized into three essential requirements: (1) Effectiveness based on scientific evidence (including clinical evidence).
(2) Safety of product (including safety studies in human subjects). (3) Analytical determination of the effective components.
After validation, and assessment of all the scientific data supplied, the MHLW makes a decision whether to grant approval for the product under FOSHU. However, with the establishment of Qualified FOSHU in 2005, where the scientific evidence may not be sufficient for full standardized FOSHU these products can be placed on the market with a qualifying statement that "evidence has not necessarily been established". In addition, the term "possibly" must be included in the description of the health claim. Administration, 1990 ). This gave the FDA clear authority to require nutrition labelling of most foods; and to require that all nutrient content claims, e.g. "high fibre", "low fat" etc. and health claims be consistent with agency regulations. Under this Act, foods with approved
health claims are not considered drugs but rather foods for general consumption. To use such a claim in association with food, the FDA was authorised to issue specific regulations describing the permitted claim. This was to enable consumers to "understand the information provided in the claim and the relative significance of such information in the context of a total daily diet". There is a tiered system of claims authorised in the USA: (1 . calcium and reduced risk of osteoporosis;
. sodium and reduced risk of hypertension;
. dietary saturated fat and cholesterol and reduced risk of coronary heart disease;
. dietary fat and reduced risk of cancer;
. fruits, vegetables and grain products that contain fibre, particularly soluble fibre, and reduced risk of coronary heart disease;
. fruits and vegetables and reduced risk of cancer;
.
folate and reduced risk of neural tube defects;
. dietary noncariogenic carbohydrate sweeteners and reduced risk of dental caries;
. soluble fibre from certain foods and reduced risk of coronary heart disease;
. soy protein and reduced risk of coronary heart disease;
. plant sterol/stanol esters and reduced risk of coronary heart disease. In accordance with the NLEA, in order to make a new claim, companies had to apply to the FDA and authorisation was granted provided specific requirements were met. First, the claim had to characterise the relationship of any substance to a disease, or health related condition, for which most people, or a specific group of people, such as the elderly are at risk. Second, for a claim to be valid, the rules required significant agreement among qualified experts that the claim was supported by the "totality of publicly available scientific evidence". (2) In 1997, with a view to speeding up the authorisation procedure, the US Congress passed the FDA Modernization Act (FDAMA) (US Food and Drug Administration, 1997) which specifically provided for the use of health claims based on authoritative statements from a scientific body of the US Government or the National Academy of Sciences. In addition, the FDAMA gave the FDA 120 days to respond to the companies' notification. If they did not act to prohibit or modify the claim within that time, the claim could be used. In accordance with this procedure, the following claims have been approved for use (US Food and Drug Administration, 2008):
. wholegrain foods and a reduction in the risk of heart disease and certain cancers;
. potassium and a reduction in the risk of high blood pressure and stroke;
. flouridated water and a reduction in the risk of dental caries; BFJ 113,2
. saturated fat, cholesterol and trans-fat and a reduction in the risk of heart disease. Claims approved under this system are known as "Health claims based on authoritative statements". This concluded that consumers would benefit from more information on food labels concerning diet and health. In addition, past court decisions clarified a need to provide for health claims based on less scientific evidence rather than just on the standard of significant scientific agreement, as long as the claims do not mislead the consumer. As a result, qualified health claims were introduced. For these claims, the quality and strength of the scientific evidence falls below that required for FDA to issue an authorizing regulation. It permits the use of a health claim where there is emerging evidence for a relationship between a food and reduced risk of a disease or health related condition. In these cases, a qualifying statement is required as part of the claim to indicate that the evidence supporting the claim is limited. Qualified health claims currently in use in the USA are:
Qualified claim about cancer risk: tomatoes and/or tomato sauce and reduced risk of prostate, ovarian, gastric and pancreatic cancer; calcium and colon/rectal cancer and calcium and reduced risk of recurring colon/rectal polyps; green tea and reduced risk of cancer; selenium and reduced risk of cancer; antioxidant vitamins and reduced risk of cancer.
. Qualified claims about cardiovascular disease risk: nuts and reduced risk of heart disease; walnuts and reduced risk of heart disease; Omega-3 fatty acids and reduced risk of coronary heart disease; B vitamins and reduced risk of vascular disease; mono-unsaturated fatty acids from olive oil and reduced risk of coronary heart disease; unsaturated fatty acids from canola oil and reduced risk of coronary heart disease; corn oil and reduced risk of heart disease.
. Qualified claims about cognitive function: phosphatidylserine and cognitive dysfunction and reduced risk of dementia.
. Qualified claims about diabetes: chromium picolinate and reduced risk of diabetes.
. Qualified claims about hypertension: calcium and reduced risk of hypertension, pregnancy induced hypertension and reduced risk of pre-eclampsia.
. Qualified claims about neural tube defects: 0.8 mg folic acid and reduced risk of neural tube defects.
II.2.2 Scientific requirements for claim approval in USA.
There have been regulatory requirements for health claims in the USA since 1990 and as outlined above, a number of changes since then. These changes have produced alternative procedures for different types of claims. These alternative procedures have resulted in a relaxation of the scientific requirements, and a distinct reduction in the levels of scientific evidence, required to support a claim. NLEA authorised claims are most rigorously assessed by the FDA,
Health claims regulations
FDAMA claims are reviewed and supported by organisations external to the FDA and finally qualified health claims, where emerging science can be considered satisfactory. NLEA or Significant Scientific Agreement (SSA) Claims (US Food and Drug Administration, 1999). As outlined above, under NLEA, a manufacturer must first apply to the FDA for authorisation prior to using a particular claim. On foot of receiving a petition from a manufacturer, the FDA will evaluate among other considerations, whether the evidence supporting the relationship that is the subject of the claim meets a "significant scientific agreement" standard.
The scientific review process FDA uses to evaluate health claims is comprehensive and focuses first on a review of individual studies. After identifying relevant, good quality studies and assessing their strengths and weaknesses, the agency conducts a more comprehensive review based on the body of evidence as a whole.
The assessment of scientific validity for a health claim includes two components:
(1) that the totality of the publicly available evidence supports the substance/disease relationship that is the subject of the claim; and (2) that there is significant scientific agreement among qualified experts that the relationship is valid.
The FDA has published guidance to the industry on the level of data required and the calibre of studies that should be conducted (US Food and Drug Administration, 1999). This guidance also outlines the assessment criteria the FDA use to establish whether, or not, significant scientific agreement exists and authorisation of the claim can be granted. Significant scientific agreement means that the validity of the relationship is not likely to be reversed by new and evolving science. To assess this for each claim, the following is required:
. Identification of data for review. Human studies, both interventions and observational studies, animal and in vitro studies should be provided. . Assessment of significant scientific agreement. SSA depends on the strength and consistency of the evidence. It cannot be reached without a strong, relevant and consistent body of evidence on which experts in the field may base a conclusion that a substance/disease relationship exists.
FDAMA claims (US Food and Drug Administration, 1997). As outlined above, in accordance with FDAMA, it was permitted to use health claims provided they were based on current, published, authoritative statements from certain federal scientific bodies, as well as from the National Academy of Sciences. It became no longer essential to supply all comprehensive scientific data to the FDA in order to apply for authorisation of a claim.
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Now a much simpler notification, based on authoritative statements from acceptable organisations became satisfactory. Once sanctioned by a reputable scientific body, the FDA will not object to the use of a particular claim. The FDA will no longer gather and assess the data in support of a FDAMA claim but has surrendered the responsibility for that to other organisations.
However, while the FDA does not conduct a comprehensive scientific evaluation of the data under FDAMA, it does uphold the "significant scientific agreement" standard for health claims. Based on the notification procedure, if the FDA believes that the totality of publicly available evidence does not support a claim, they can issue a regulation to prohibit its use.
Qualified health claims (US Food and Drug Administration, 2006). Qualified health claims differ from Significant Scientific Agreement (SSA) claims in that they must be accompanied by a disclaimer or otherwise qualified (see Table I ). In the case of qualified health claims, as with SSA claims, a petition must be submitted to the FDA for approval. Qualified health claims are still based on the totality of publicly available evidence but, based on an interim procedure, the scientific support does not have to be as strong as that for significant scientific agreement. (1) Nutrition claims. A nutrition claim is one which states, suggests, or implies that a food has particular beneficial nutritional property due to the energy, nutrients, or other substances provided, not provided or produced in reduced/increased amounts. The appendix to this legislation provides a list of permitted claims and the conditions applying to them. For example to claim that a product is "low energy", the product must have less than 40 kcal/100 g for solids and less than 20kcal/100 ml for liquids. Article 13.1 claims are based on "generally accepted scientific evidence" and only "references to the relevant scientific justification" are required when suggesting such claims. However claims based on newly developed scientific evidence, Article 13.5 claims, require the submission of an extensive dossier. In a similar vein, because disease risk reduction claims were previously prohibited and claims relating to the children's development and growth were deemed to be targeting a particularly vulnerable population, an extensive dossier is now required for their application (Article 14 claims).
To date, EFSA has published opinions on 41 different Article 14 claims, the majority of which pertain to children's development and health. EFSA has approved eight of these claims, the details of which are outlined in Table III. II.3.2 Scientific requirements in European Union. One of the most important parts of the Regulation 1924/2006 on nutrition and health claims is that scientific substantiation is the major cornerstone on which authorisation for the use of health claims will be granted. In this regards, the regulation acknowledges and references, the Process for the Assessment of Scientific Support for Claim on Foods (PASSCLAIM) project (Asp and Bryngelsson, 2008) . This project engaged more than 160 scientists from academia, industry, research institutes, public interest groups and the regulatory environment and its primary objective was to produce a generic tool for assessing the scientific support for health claims in foods (Asp and Contor, 2003) . It concluded the following generally applicable criteria for the scientific support of claims. These criteria: The exact text provided is that which, according to EFSA, reflects the scientific evidence Has the product been sufficiently characterised?
Is the product/claimed effect beneficial for health? Comprehensive scientific data is necessary, including tabulated, and written, summaries of data from pertinent human and non human, studies whether they are interventions or observational studies, experimental or quasi experimental, randomised, controlled etc. The application form is very specific and detailed and it specifies the requirement to provide both published and unpublished data. Table IV provides a summary of the regulatory systems across the different countries.
Part IV. Comparison across countries
Different countries view claims differently, employ different standards for levels of scientific evidence and different processes for evaluation. The level of evidence required in one country may not meet the requirements in another so claims that are permitted in one location may be prohibited elsewhere.
High level of scientific evidence
As outlined above, the requirement for SSA claims in the USA, the FOSHU claims in Japan and Article 13 (5) and Article 14 health claims in Europe all require detailed scientific assessment and review. There are similar rules in different countries but claims are categorised differently, which can result in different outcomes.
Lower level of scientific evidence Qualified health claims in the USA and Qualified FOSHU in Japan are similar in nature. Both accept that a food or product may have some beneficial effect, without all the science to support it. In Europe there is no such claim category for those with weaker levels of scientific evidence. These are allowed to use labels that inform consumers who ingest the food for specific health purposes that their purpose may be achieved by consuming the product (continued) A FOSHU with a label containing any indication of a reduction of risks of developing certain diseases. At this moment, food containing calcium (reducing risk of osteoporosis) or folic acid (reducing risk of neural tube defects) are permitted. However, in issuing an approval, the label will be required to contain a sufficient warning that the relevant disease has many risk factors and that sufficient exercise is also required for healthy life. The label also will be required to contain a sufficient warning for excessive intake Table IV. BFJ 113,2
In the USA and Japan, there is a view that there are benefits from an approach alternative to full authorisation for claims. It was considered that industry would benefit by getting their products to market sooner and there could be a public health benefit when consumers have access to a wider range of products. Qualified health claims were introduced in both countries whereby and when relevant, a statement to the effect that all the science may not be available to support a specific claim but there may be an effect, must be made. This statement is designed to enable consumers distinguish between these claims and those approved as a result of substantial scientific evidence of efficacy. However, some studies have indicated that consumers do not make this distinction. A study in the USA by the International Food Information Council showed that 78 per cent of consumers could not correctly sort different claims as to the different level of supporting scientific evidence (International Food Information Council, 2007) . These findings were corroborated by Hooker and Teratanavat in 2008 where their study suggests that consumers are not yet able to distinguish between the different types of health claims and the strength of science on which the claim is based (Hooker and Teratanavat, 2008) .
This complicated situation leaves us with the question as to the appropriate degree of regulation that is required. It is important that the consumer be protected but also that they are offered choices which may benefit their health. In addition, it is also important that the industry be allowed to grow, develop and compete internationally. The consumer must be supplied with the information in a manner where they understand and ultimately believe what they read. Clearly regulated health claims are the route to achieving this aim. The challenge to the regulators is how to strike a balance between preventing false and misleading information from reaching consumers while encouraging the use of foods to attain a healthy lifestyle.
The regulatory systems in the USA and Japan have accepted that there may be potential in permitting the use of claims where the supporting scientific evidence is not significant. However even in cases where full authorisation for a claim is applied for, the level of evidence required for foods with health claims extends only as far as dietary intervention. If, as is the case in the USA and Japan, there's a weakening of the 
